RayzeBio, Inc. Common Stock (RYZB) Stock Analysis
DELISTED 2024
What happened to RayzeBio, Inc. Common Stock (RYZB) stock?
RayzeBio, Inc. Common Stock (RYZB) no longer trades on public markets. It was delisted in February 2024. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- February 2024
- Last recorded price (historical):
- $62.49 (last quote on record before the February 2024 delisting; historical, not a current quote)
Market cap $3.75B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
RayzeBio, Inc. Common Stock (RYZB). RayzeBio, Inc. is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical therapeutics (RPTs) for cancer treatment. Their lead drug candidate, RYZ101, is currently in Phase 3 clinical trials for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Last analyzed: Mar 18, 2026RayzeBio, Inc. Common Stock (RYZB) Healthcare & Pipeline Overview
More about this archive record
Can I still buy RYZB shares?
No. RYZB stopped trading on public markets in February 2024, so the shares are not available through a broker. Anything you see quoted for RYZB elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RYZB stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to RayzeBio, Inc. Common Stock. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.